Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects

NCT01203384 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: CHF5074 1x
DRUG: CHF5074 2x
DRUG: CHF5074 3x
DRUG: Placebo

Sponsor

CERESPIR